Date: 2011-05-18
Type of information:
phase: 1
Announcement: recruitment of the first patients
Company: Glycotope (Germany)
Product: FSH-GEX®
Action mechanism:
Disease: in vitro fertilisation
anovulatory infertility
Therapeutic area: Gynecology - Women's health
Country: the Netherlands
Trial details:
Latest news: Glycotope has recently received approvals to initiate clinical trials for its first glycooptimized non-antibody protein therapeutic FSH-GEX®. The German company has now enrolled its first patients in the phase I trial of this follicle-stimulating hormone which will be developed for in vitro fertilisation and the treatment of anovulatory infertility.
